Management of Breakthrough Seizures with Therapeutic Levetiracetam Levels

Immediate Management of Refractory Status Epilepticus

IV valproate (30 mg/kg), IV levetiracetam (60 mg/kg, max 4.5 g), or IV phenytoin/fosphenytoin (18–20 mg/kg) can be used as second‑line agents, achieving comparable seizure‑cessation rates of ≈45–47% in benzodiazepine‑refractory status epilepticus (American Academy of Neurology guideline, Level A evidence)【1】.
Levetiracetam offers a superior safety profile versus fosphenytoin: hypotension occurs in ~0.7% of patients receiving levetiracetam compared with 3.2% with fosphenytoin, and respiratory‑depression rates are lower with levetiracetam【2】 (clinical evidence).

When seizures persist despite therapeutic levetiracetam concentrations, add an adjunctive antiseizure medication such as valproate, lamotrigine, or lacosamide rather than increasing the levetiracetam dose【1】 (American Academy of Neurology recommendation).

Levetiracetam is associated with significantly fewer adverse events than phenobarbital in head‑to‑head comparisons【2】 (clinical evidence).
Cardiac monitoring is not required during levetiracetam infusion, unlike with phenytoin or fosphenytoin, simplifying emergency administration【2】 (clinical evidence).